Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2021 | COVID-19 outcomes for myeloma patients receiving lenalidomide maintenance

Meral Beksac • 8 Mar 2021
EMN 2021
Multiple Myeloma Lenalidomide

Meral Beksac, MD, Ankara University, Ankara, Turkey, gives an overview of study investigating the outcomes of patients with COVID-19 infections who are receiving lenalidomide maintenance therapy, as presented at EMN 2021. Data was analyzed from 48 patients with multiple myeloma who were also diagnosed with a COVID-19 infection. The study found that patients receiving lenalidomide maintenance therapy had a COVID-19 infection fatality rate of 30.4%, compared to a rate of 48% for patients who were not receiving lenalidomide maintenance therapy. This interview took place during the 2021 European Myeloma Network (EMN) congress.

More from Meral Beksac

3:36
Ex vivo expanded NK cells for hematological cancer immunotherapy
Meral Beksac • 11 Dec 2023
3:52
EMN19: Dara-VCd in patients with multiple myeloma and extramedullary disease
Meral Beksac • 12 Dec 2023
2:16
The value of the early relapse EBMT score in multiple myeloma
Meral Beksac • 28 Sep 2023
1:30
Exploring the role of upfront autoSCT in multiple myeloma
Meral Beksac • 28 Sep 2023

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
1:33
Post-hoc analysis of TOURMALINE-MM1 data while adjusting for subsequent therapies
Karthik Ramasamy • 28 Apr 2024
4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals